The global Live Attenuated Influenza Vaccine (LAIV) market was valued at US$ 7740.5 million in 2023 and is anticipated to reach US$ 11700 million by 2030, witnessing a CAGR of 6.3% during the forecast period 2024-2030.

Live Attenuated Influenza Vaccine (LAIV) Market

A Live Attenuated Influenza Vaccine (LAIV), also known as the "nasal spray" or "intranasal" flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.

Evolving Vaccine Formulations: The LAIV formulation changes annually to match the prevalent influenza virus strains. Researchers continually monitor and adapt the vaccine to ensure it provides protection against the most relevant strains. This requires ongoing research and development efforts.

Preference for Non-Invasive Vaccination: The nasal spray administration method of LAIV is preferred by some individuals, particularly children and those who are averse to needles. This preference has driven demand for LAIV, especially among pediatric populations.

Efficacy and Effectiveness Research: Ongoing research is aimed at improving the effectiveness and stability of LAIV. Ensuring the vaccine's effectiveness is crucial in maintaining public confidence and its role in influenza prevention.

Enhanced Cold Chain Management: As LAIV is a live vaccine, it requires specific storage and transport conditions to maintain its viability. Advances in cold chain management are essential to preserve the vaccine's effectiveness.

Global Variations in Approval: Approval and recommendations for LAIV can vary by country and region. Some countries may be more enthusiastic about LAIV, while others may have specific guidelines and restrictions regarding its use.

This report aims to provide a comprehensive presentation of the global market for Live Attenuated Influenza Vaccine (LAIV), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Influenza Vaccine (LAIV).

Report Scope

The Live Attenuated Influenza Vaccine (LAIV) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Live Attenuated Influenza Vaccine (LAIV) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Live Attenuated Influenza Vaccine (LAIV) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Live Attenuated Influenza Vaccine (LAIV) Market Report

Report Metric	Details
Report Name	Live Attenuated Influenza Vaccine (LAIV) Market
Accounted market size in 2023	US$ 7740.5 million
Forecasted market size in 2030	US$ 11700 million
CAGR	6.3%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Trivalent Flu Vaccine Quadrivalent Flu Vaccine
Segment by Application	Hospital Clinic Public Health Agency Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Sanofi Pasteur, AstraZeneca, CSL, Abbott, GlaxoSmithKline, Serum Institute, Fluenz Tetra, Cytiva, BioDiem, FluMist, GSK, ChangChun High & New Technology, BCHT Biotechnology
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Live Attenuated Influenza Vaccine (LAIV) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Live Attenuated Influenza Vaccine (LAIV) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Live Attenuated Influenza Vaccine (LAIV) Market growing?

Ans: The Live Attenuated Influenza Vaccine (LAIV) Market witnessing a CAGR of 6.3% during the forecast period 2024-2030.

What is the Live Attenuated Influenza Vaccine (LAIV) Market size in 2030?

Ans: The Live Attenuated Influenza Vaccine (LAIV) Market size in 2030 will be US$ 11700 million.

Who are the main players in the Live Attenuated Influenza Vaccine (LAIV) Market report?

Ans: The main players in the Live Attenuated Influenza Vaccine (LAIV) Market are Sanofi Pasteur, AstraZeneca, CSL, Abbott, GlaxoSmithKline, Serum Institute, Fluenz Tetra, Cytiva, BioDiem, FluMist, GSK, ChangChun High & New Technology, BCHT Biotechnology

What are the Application segmentation covered in the Live Attenuated Influenza Vaccine (LAIV) Market report?

Ans: The Applications covered in the Live Attenuated Influenza Vaccine (LAIV) Market report are Hospital, Clinic, Public Health Agency, Other

What are the Type segmentation covered in the Live Attenuated Influenza Vaccine (LAIV) Market report?

Ans: The Types covered in the Live Attenuated Influenza Vaccine (LAIV) Market report are Trivalent Flu Vaccine, Quadrivalent Flu Vaccine

1 Live Attenuated Influenza Vaccine (LAIV) Market Overview

1.1 Product Overview and Scope of Live Attenuated Influenza Vaccine (LAIV)

1.2 Live Attenuated Influenza Vaccine (LAIV) Segment by Type

1.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Value Comparison by Type (2024-2030)

1.2.2 Trivalent Flu Vaccine

1.2.3 Quadrivalent Flu Vaccine

1.3 Live Attenuated Influenza Vaccine (LAIV) Segment by Application

1.3.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Value by Application: (2024-2030)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Public Health Agency

1.3.5 Other

1.4 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Estimates and Forecasts

1.4.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue 2019-2030

1.4.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales 2019-2030

1.4.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Live Attenuated Influenza Vaccine (LAIV) Market Competition by Manufacturers

2.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturers (2019-2024)

2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Manufacturers (2019-2024)

2.4 Global Live Attenuated Influenza Vaccine (LAIV) Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Product Type & Application

2.7 Live Attenuated Influenza Vaccine (LAIV) Market Competitive Situation and Trends

2.7.1 Live Attenuated Influenza Vaccine (LAIV) Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Live Attenuated Influenza Vaccine (LAIV) Players Market Share by Revenue

2.7.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Live Attenuated Influenza Vaccine (LAIV) Retrospective Market Scenario by Region

3.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Live Attenuated Influenza Vaccine (LAIV) Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region: 2019-2030

3.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region: 2019-2024

3.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region: 2025-2030

3.3 Global Live Attenuated Influenza Vaccine (LAIV) Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region: 2019-2030

3.3.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region: 2019-2024

3.3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region: 2025-2030

3.4 North America Live Attenuated Influenza Vaccine (LAIV) Market Facts & Figures by Country

3.4.1 North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2030)

3.4.3 North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Live Attenuated Influenza Vaccine (LAIV) Market Facts & Figures by Country

3.5.1 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2030)

3.5.3 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Facts & Figures by Country

3.6.1 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2030)

3.6.3 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Live Attenuated Influenza Vaccine (LAIV) Market Facts & Figures by Country

3.7.1 Latin America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2030)

3.7.3 Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Facts & Figures by Country

3.8.1 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2030)

3.8.3 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2019-2030)

4.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2019-2024)

4.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2025-2030)

4.1.3 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2019-2030)

4.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2019-2030)

4.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2019-2024)

4.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2025-2030)

4.2.3 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2019-2030)

4.3 Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2019-2030)

5 Segment by Application

5.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2019-2030)

5.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2019-2024)

5.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2025-2030)

5.1.3 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2019-2030)

5.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2019-2030)

5.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2019-2024)

5.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2025-2030)

5.2.3 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2019-2030)

5.3 Global Live Attenuated Influenza Vaccine (LAIV) Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Sanofi Pasteur

6.1.1 Sanofi Pasteur Corporation Information

6.1.2 Sanofi Pasteur Description and Business Overview

6.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.1.5 Sanofi Pasteur Recent Developments/Updates

6.2 AstraZeneca

6.2.1 AstraZeneca Corporation Information

6.2.2 AstraZeneca Description and Business Overview

6.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.2.4 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.2.5 AstraZeneca Recent Developments/Updates

6.3 CSL

6.3.1 CSL Corporation Information

6.3.2 CSL Description and Business Overview

6.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.3.4 CSL Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.3.5 CSL Recent Developments/Updates

6.4 Abbott

6.4.1 Abbott Corporation Information

6.4.2 Abbott Description and Business Overview

6.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.4.5 Abbott Recent Developments/Updates

6.5 GlaxoSmithKline

6.5.1 GlaxoSmithKline Corporation Information

6.5.2 GlaxoSmithKline Description and Business Overview

6.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.5.4 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.5.5 GlaxoSmithKline Recent Developments/Updates

6.6 Serum Institute

6.6.1 Serum Institute Corporation Information

6.6.2 Serum Institute Description and Business Overview

6.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.6.5 Serum Institute Recent Developments/Updates

6.7 Fluenz Tetra

6.6.1 Fluenz Tetra Corporation Information

6.6.2 Fluenz Tetra Description and Business Overview

6.6.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.7.5 Fluenz Tetra Recent Developments/Updates

6.8 Cytiva

6.8.1 Cytiva Corporation Information

6.8.2 Cytiva Description and Business Overview

6.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.8.5 Cytiva Recent Developments/Updates

6.9 BioDiem

6.9.1 BioDiem Corporation Information

6.9.2 BioDiem Description and Business Overview

6.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.9.4 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.9.5 BioDiem Recent Developments/Updates

6.10 FluMist

6.10.1 FluMist Corporation Information

6.10.2 FluMist Description and Business Overview

6.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.10.4 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.10.5 FluMist Recent Developments/Updates

6.11 GSK

6.11.1 GSK Corporation Information

6.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Description and Business Overview

6.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.11.4 GSK Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.11.5 GSK Recent Developments/Updates

6.12 ChangChun High & New Technology

6.12.1 ChangChun High & New Technology Corporation Information

6.12.2 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Description and Business Overview

6.12.3 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.12.4 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.12.5 ChangChun High & New Technology Recent Developments/Updates

6.13 BCHT Biotechnology

6.13.1 BCHT Biotechnology Corporation Information

6.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Description and Business Overview

6.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)

6.13.4 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Portfolio

6.13.5 BCHT Biotechnology Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Live Attenuated Influenza Vaccine (LAIV) Industry Chain Analysis

7.2 Live Attenuated Influenza Vaccine (LAIV) Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Live Attenuated Influenza Vaccine (LAIV) Production Mode & Process

7.4 Live Attenuated Influenza Vaccine (LAIV) Sales and Marketing

7.4.1 Live Attenuated Influenza Vaccine (LAIV) Sales Channels

7.4.2 Live Attenuated Influenza Vaccine (LAIV) Distributors

7.5 Live Attenuated Influenza Vaccine (LAIV) Customers

8 Live Attenuated Influenza Vaccine (LAIV) Market Dynamics

8.1 Live Attenuated Influenza Vaccine (LAIV) Industry Trends

8.2 Live Attenuated Influenza Vaccine (LAIV) Market Drivers

8.3 Live Attenuated Influenza Vaccine (LAIV) Market Challenges

8.4 Live Attenuated Influenza Vaccine (LAIV) Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

ChangChun High & New Technology

Bcht Biotechnology

List of Tables

Table 1. Global Live Attenuated Influenza Vaccine (LAIV) Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Live Attenuated Influenza Vaccine (LAIV) Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Live Attenuated Influenza Vaccine (LAIV) Market Competitive Situation by Manufacturers in 2023

Table 4. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Live Attenuated Influenza Vaccine (LAIV), Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Product Type & Application

Table 12. Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Live Attenuated Influenza Vaccine (LAIV) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Influenza Vaccine (LAIV) as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K Units)

Table 18. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2019-2024)

Table 19. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2025-2030) & (K Units)

Table 20. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2025-2030)

Table 21. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2019-2024)

Table 23. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2025-2030)

Table 25. North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K Units)

Table 27. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2025-2030) & (K Units)

Table 28. North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K Units)

Table 32. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2025-2030) & (K Units)

Table 33. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units) by Type (2019-2024)

Table 51. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units) by Type (2025-2030)

Table 52. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2019-2024)

Table 53. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2025-2030)

Table 54. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2019-2024)

Table 57. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2025-2030)

Table 58. Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit) by Type (2019-2024)

Table 59. Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit) by Type (2025-2030)

Table 60. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units) by Application (2019-2024)

Table 61. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units) by Application (2025-2030)

Table 62. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2019-2024)

Table 63. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2025-2030)

Table 64. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2019-2024)

Table 67. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2025-2030)

Table 68. Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit) by Application (2019-2024)

Table 69. Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit) by Application (2025-2030)

Table 70. Sanofi Pasteur Corporation Information

Table 71. Sanofi Pasteur Description and Business Overview

Table 72. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product

Table 74. Sanofi Pasteur Recent Developments/Updates

Table 75. AstraZeneca Corporation Information

Table 76. AstraZeneca Description and Business Overview

Table 77. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product

Table 79. AstraZeneca Recent Developments/Updates

Table 80. CSL Corporation Information

Table 81. CSL Description and Business Overview

Table 82. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. CSL Live Attenuated Influenza Vaccine (LAIV) Product

Table 84. CSL Recent Developments/Updates

Table 85. Abbott Corporation Information

Table 86. Abbott Description and Business Overview

Table 87. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Abbott Live Attenuated Influenza Vaccine (LAIV) Product

Table 89. Abbott Recent Developments/Updates

Table 90. GlaxoSmithKline Corporation Information

Table 91. GlaxoSmithKline Description and Business Overview

Table 92. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product

Table 94. GlaxoSmithKline Recent Developments/Updates

Table 95. Serum Institute Corporation Information

Table 96. Serum Institute Description and Business Overview

Table 97. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product

Table 99. Serum Institute Recent Developments/Updates

Table 100. Fluenz Tetra Corporation Information

Table 101. Fluenz Tetra Description and Business Overview

Table 102. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product

Table 104. Fluenz Tetra Recent Developments/Updates

Table 105. Cytiva Corporation Information

Table 106. Cytiva Description and Business Overview

Table 107. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product

Table 109. Cytiva Recent Developments/Updates

Table 110. BioDiem Corporation Information

Table 111. BioDiem Description and Business Overview

Table 112. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product

Table 114. BioDiem Recent Developments/Updates

Table 115. FluMist Corporation Information

Table 116. FluMist Description and Business Overview

Table 117. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. FluMist Live Attenuated Influenza Vaccine (LAIV) Product

Table 119. FluMist Recent Developments/Updates

Table 120. GSK Corporation Information

Table 121. GSK Description and Business Overview

Table 122. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. GSK Live Attenuated Influenza Vaccine (LAIV) Product

Table 124. GSK Recent Developments/Updates

Table 125. ChangChun High & New Technology Corporation Information

Table 126. ChangChun High & New Technology Description and Business Overview

Table 127. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product

Table 129. ChangChun High & New Technology Recent Developments/Updates

Table 130. BCHT Biotechnology Corporation Information

Table 131. BCHT Biotechnology Description and Business Overview

Table 132. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product

Table 134. BCHT Biotechnology Recent Developments/Updates

Table 135. Key Raw Materials Lists

Table 136. Raw Materials Key Suppliers Lists

Table 137. Live Attenuated Influenza Vaccine (LAIV) Distributors List

Table 138. Live Attenuated Influenza Vaccine (LAIV) Customers List

Table 139. Live Attenuated Influenza Vaccine (LAIV) Market Trends

Table 140. Live Attenuated Influenza Vaccine (LAIV) Market Drivers

Table 141. Live Attenuated Influenza Vaccine (LAIV) Market Challenges

Table 142. Live Attenuated Influenza Vaccine (LAIV) Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Live Attenuated Influenza Vaccine (LAIV)

Figure 2. Global Live Attenuated Influenza Vaccine (LAIV) Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Type in 2023 & 2030

Figure 4. Trivalent Flu Vaccine Product Picture

Figure 5. Quadrivalent Flu Vaccine Product Picture

Figure 6. Global Live Attenuated Influenza Vaccine (LAIV) Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application in 2023 & 2030

Figure 8. Hospital

Figure 9. Clinic

Figure 10. Public Health Agency

Figure 11. Other

Figure 12. Global Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (2019-2030) & (US$ Million)

Figure 14. Global Live Attenuated Influenza Vaccine (LAIV) Sales (2019-2030) & (K Units)

Figure 15. Global Live Attenuated Influenza Vaccine (LAIV) Average Price (US$/Unit) & (2019-2030)

Figure 16. Live Attenuated Influenza Vaccine (LAIV) Report Years Considered

Figure 17. Live Attenuated Influenza Vaccine (LAIV) Sales Share by Manufacturers in 2023

Figure 18. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers in 2023

Figure 19. The Global 5 and 10 Largest Live Attenuated Influenza Vaccine (LAIV) Players: Market Share by Revenue in 2023

Figure 20. Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 21. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 22. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2019-2030)

Figure 23. North America Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2019-2030)

Figure 24. United States Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Canada Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2019-2030)

Figure 27. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2019-2030)

Figure 28. Germany Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. France Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. U.K. Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Italy Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Russia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2019-2030)

Figure 34. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2019-2030)

Figure 35. China Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Japan Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. South Korea Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. India Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Australia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. China Taiwan Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Indonesia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Thailand Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Malaysia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Latin America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2019-2030)

Figure 45. Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2019-2030)

Figure 46. Mexico Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Brazil Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Argentina Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2019-2030)

Figure 50. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2019-2030)

Figure 51. Turkey Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. UAE Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Global Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2019-2030)

Figure 55. Global Revenue Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2019-2030)

Figure 56. Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit) by Type (2019-2030)

Figure 57. Global Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Application (2019-2030)

Figure 58. Global Revenue Market Share of Live Attenuated Influenza Vaccine (LAIV) by Application (2019-2030)

Figure 59. Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit) by Application (2019-2030)

Figure 60. Live Attenuated Influenza Vaccine (LAIV) Value Chain

Figure 61. Live Attenuated Influenza Vaccine (LAIV) Production Process

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Distributors Profiles

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions